Mechanism of Action: Adenosine Receptor Agonists
✉ Email this page to a colleague
Drugs with Mechanism of Action: Adenosine Receptor Agonists
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dr Reddys | REGADENOSON | regadenoson | SOLUTION;INTRAVENOUS | 213210-001 | Apr 11, 2022 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Ims Ltd | REGADENOSON | regadenoson | SOLUTION;INTRAVENOUS | 214252-001 | May 23, 2022 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Apotex | REGADENOSON | regadenoson | SOLUTION;INTRAVENOUS | 207604-001 | Apr 11, 2022 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Accord Hlthcare | REGADENOSON | regadenoson | SOLUTION;INTRAVENOUS | 213236-001 | Apr 11, 2022 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Hospira | REGADENOSON | regadenoson | SOLUTION;INTRAVENOUS | 214349-001 | Aug 31, 2022 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Mylan | REGADENOSON | regadenoson | SOLUTION;INTRAVENOUS | 213856-001 | Apr 4, 2023 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Gland Pharma Ltd | REGADENOSON | regadenoson | SOLUTION;INTRAVENOUS | 207320-001 | Jul 12, 2022 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |